The positive CHMP opinion is a major derisking event for European approval. Traders should watch for the EC decision in 2H26 as the next catalyst. The PREVAIL cardiovascular outcomes trial readout will be the next major binary event for U.S. approval prospects. The stock is likely to re-rate on this regulatory progress.
Price Chart
Executive Summary
NewAmsterdam Pharma announced that the EMA's CHMP has adopted a positive opinion recommending marketing authorization for Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib plus ezetimibe fixed-dose combination) in Europe. The European Commission is expected to issue a final decision in 2H26, and if approved, this would enable commercialization of obicetrapib across EU member states, Iceland, Liechtenstein, and Norway, unlocking milestone payments of up to €833 million for NewAmsterdam plus tiered double-digit royalties on net sales in the Menarini territory.
Key Facts
- CHMP adopted a positive opinion recommending marketing authorization for Ubeslo (obicetrapib 10 mg monotherapy) and Evlarco (10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination).
- Recommendation is supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM data showing up to ~40% LDL-C reduction with obicetrapib monotherapy and ~50% with the combination vs placebo.
- European Commission decision expected in 2H26; if granted, authorization applies across all EU member states plus Iceland, Liechtenstein, and Norway.
- NewAmsterdam is entitled to up to €833 million in clinical, regulatory, and commercial milestones plus tiered double-digit royalties (low double-digits to mid-twenties) on net sales in the Menarini territory.
- Menarini holds exclusive commercialization rights for obicetrapib in Europe and is responsible for regulatory interactions and commercialization.
Financial Impact
Up to €833 million in milestone payments plus tiered double-digit percentage royalties on European net sales
Risk Factors
- EC may not grant final marketing authorization despite CHMP positive opinion
- Commercial uptake in Europe depends on pricing and reimbursement negotiations
- PREVAIL cardiovascular outcomes trial results remain a key binary risk for full commercial potential
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-315163 |
| Document: nams-ex99_1.htm | 0001193125-26-315163 |
| Document: 0001193125-26-315163-index-headers.html | 0001193125-26-315163 |
| Document: 0001193125-26-315163-index.html | 0001193125-26-315163 |
| Document: 0001193125-26-315163.txt | 0001193125-26-315163 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Buy | $21.16 $23.32 | ▲ +10.21% | ▲ +8.08% | $23.20 (+9.64%) |
Aug 5, 2026 8w ago | 8-K | $27.42 $27.83 | ▲ +1.50% | ▲ +1.14% | $23.20 (−15.39%) |
Jul 24, 2026 10w ago | 8-K | $29.64 $28.46 | ▼ −3.98% | ▼ −4.35% | $23.20 (−21.73%) |
Apr 8, 2026 25w ago | Press Release | $34.01 $34.01 | · 0.00% | ▼ −3.52% | $23.20 (−31.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access